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Background: Leber hereditary optic neuropathy (LHON)
leads to bilateral central vision loss. In a clinical trial
setting, idebenone has been shown to be safe and to
provide a trend toward improved visual acuity, but long-term
evidence of effectiveness in real-world clinical practice is
sparse.
Methods: Open-label, multicenter, retrospective, non-
controlled analysis of long-term visual acuity and safety in
111 LHON patients treated with idebenone (900 mg/day) in
an expanded access program. Eligible patients had a con-
firmed mitochondrial DNA mutation and had experienced
the onset of symptoms (most recent eye) within 1 year
before enrollment. Data on visual acuity and adverse events
were collected as per normal clinical practice. Efficacy was
assessed as the proportion of patients with either a clini-
cally relevant recovery (CRR) or a clinically relevant stabili-
zation (CRS) of visual acuity. In the case of CRR, time to and
magnitude of recovery over the course of time were also
assessed.
Results: At time of analysis, 87 patients had provided
longitudinal efficacy data. Average treatment duration was
25.6 months. CRR was observed in 46.0% of patients.
Analysis of treatment effect by duration showed that the
proportion of patients with recovery and the magnitude of
recovery increased with treatment duration. Average gain in
best-corrected visual acuity for responders was 0.72 loga-
rithm of the minimal angle of resolution (logMAR), equiva-
lent to more than 7 lines on the Early Treatment Diabetic
Retinopathy Study (ETDRS) chart. Furthermore, 50% of pa-
tients who had a visual acuity below 1.0 logMAR in at least
one eye at initiation of treatment successfully maintained
their vision below this threshold by last observation. Ide-
benone was well tolerated, with most adverse events clas-
sified as minor.
Conclusions: These data demonstrate the benefit of idebe-
none treatment in recovering lost vision and maintaining
good residual vision in a real-world setting. Together, these
findings indicate that idebenone treatment should be initi-
ated early and be maintained more than 24 months to
maximize efficacy. Safety results were consistent with the
known safety profile of idebenone.
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L eber hereditary optic neuropathy (LHON) is a form ofblindness due to retinal ganglion cell dysfunction (1),
caused by mutations in mitochondrial DNA (mtDNA),
which affect complex I (NADH-ubiquinone oxidoreduc-
tase) of the mitochondrial respiratory chain (2,3). Although
rare (estimated prevalence of 1 in 27,000–45,000), it affects
all ages and gender, causing rapid and severe, bilateral (usu-
ally sequential), painless loss of central vision (4–7). Spon-
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taneous recovery is rare (8–11). Idebenone is a synthetic
short-chain benzoquinone that bypasses the dysfunctional
complex I and restores mitochondrial function, thus
increasing ATP production and reducing lipid peroxidation
and oxidative stress (12–14).
The first randomized double-blind placebo-controlled
trial of idebenone in LHON patients (Rescue of Hereditary
Optic Disease Outpatient Study [RHODOS]) demon-
strated a trend toward an improved best-corrected visual
acuity (BCVA) in the idebenone-treated intent-to-treat
population compared with placebo (15). Idebenone (Rax-
one, idebenone 150 mg tablets, Santhera Pharmaceuticals,
Pratteln, Switzerland) is since 2015 the first and currently
the only approved treatment (European Medicines Agency
(EMA) approval in the European Union and some other
countries) for adults and adolescents with LHON.
In 2011, the manufacturer setup an international
Expanded Access Program (EAP) to provide special access to
idebenone, within local regulations, provided they had
a genetically confirmed LHON and disease duration of less
than 12 months since the onset of vision loss (most recently
affected eye). All requests for access to idebenone were
unsolicited, and the manufacturer was not involved in any
clinical decision. Here, we describe the EAP patient population
and report on clinical outcomes and safety, after ongoing long-
term treatment with idebenone in clinical practice.
METHODS
The idebenone dose and duration of therapy were entirely
at the discretion of the treating physician. Patient follow-up
was in accordance with routine clinical practice, typically at
3-month intervals.
For each participant, data on visual acuity (VA) and
adverse events (AEs) were collected. The BCVA was
generally assessed using Early Treatment Diabetic Retinop-
athy Study (ETDRS) charts with logarithm of the minimal
angle of resolution (logMAR) values or converted from
standard Snellen notation to logMAR for analysis purposes
(16). Efficacy was evaluated by outcome criteria. Clinically
relevant stabilization (CRS) of BCVA was defined as
a patient having a logMAR of ,1.0 at baseline (above the
threshold of severe vision loss/legal blindness in the United
States (17)) in at least one eye that was maintained in this
eye at their last observation visit (LV). A clinically relevant
recovery (CRR) of BCVA was defined as an improvement
from off-chart (i.e., unable to read any letters on an ETDRS
chart from 1 m;.1.68 logMAR) to on-chart by at least one
full line (5 letters), or an improvement in an on-chart
BCVA by at least 2 lines (10 letters; 0.2 logMAR). The
time to initial observation of a CRR was taken as the crite-
rion for an event-based analysis, and the magnitude of
recovery is reported as the best recovery observed for
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a patient. Safety and pregnancy information was collected
according to the applicable pharmacovigilance (PV) require-
ments (see Supplemental Digital Content, Data E1,
http://links.lww.com/WNO/A407).
Ethics approval was obtained by the Ethical Committee
of the Ludwig-Maximilian University of Munich in
accordance with the Declaration of Helsinki.
RESULTS
At the time of data cut-off (June 2018), 111 patients from
38 sites in 10 countries had received at least one dose of
idebenone and were included in the safety population (SP).
Of those, all 87 patients, who carried one of the 3 major
LHON mtDNA mutations, had a symptom onset within
the 12 months previous to the start of treatment and who
had baseline data and at least one follow-up visit with
BCVA data after baseline were included in the efficacy
population (EP). A flowchart of patients qualifying for
safety and efficacy populations or nonqualifying is shown in
Supplemental Digital Content, Figure E1, http://links.
lww.com/WNO/A407. The mean treatment duration was
25.6 months (2.4–70.4) (Table 1).
Patient demographics were generally representative of
the known disease characteristics of LHON. Three patients,
all G11778A carriers, reportedly had one eye declared
unaffected at baseline, namely, a 14-year-old boy, a 16-year-
old boy and a 21-year-old woman.
Clinically Relevant Stabilization of BCVA
In the EP, 24 of the 87 subjects had a BCVA at baseline
better than ,1.0 logMAR in at least one eye, 50% (12/24)
of whom experienced CRS (Table 1 and 2). For patients
with CRS, the mean BCVA improved from 0.47 logMAR
at baseline to 0.29 logMAR at the LV.
Of the 3 patients with one unaffected eye at baseline,
the 16-year-old patient deteriorated to an off-chart
BCVA in both eyes after 6 months of therapy, with no
recovery at the LV. However, both the 14-year-old male
patient and the 21-year-old female patient still had
a normal BCVA at the LV after 12 months’ follow-up.
These 2 patients also had a CRR in the fellow eye, which
had presented with a BCVA worse than 1.0 logMAR at
start of treatment.
Clinically Relevant Recovery of BCVA from
Nadir
Of the 87 patients, 40 patients (46.0%) (by eyes, 67/173;
38.7%) had a CRR from nadir to the LV (Table 3). The
proportion of eyes with a CRR is lower than the proportion
of patients with a CRR because not all patients experienced
recovery in both eyes. Time to initial observation in patients
with a CRR varied between 2.5 and 26.5 months, with
a mean of 9.5 months (Fig. 1). The magnitude of recovery
of patient’s best recovering eye averaged 0.45 logMAR at
initial observation of CRR and increased to 0.72 logMAR
by the LV. This increase of the magnitude of response with
longer treatment duration is confirmed when the magnitude
of CRR was analyzed specifically in 22 eyes that had dem-
onstrated a CRR by 6 months and for which follow-up data
of 12 month or longer were available (Fig. 2, right). Eyes that
eventually achieve a CRR and important VA improvement
can, nevertheless, show some degree of transient deterioration
into a nadir, despite the start of treatment (Fig. 2, left and
Supplemental Digital Content, Data E2, http://links.lww.
com/WNO/A408). Eyes can show a CRR regardless of VA
category achieved at nadir. For 173 eyes in 87 patients (one
patient’s eye had vision loss attributed to another ocular
pathology), at nadir 86 (49.7%) were off-chart; 76
(43.9%) had a BCVA 1.0—1.68 logMAR; and 11 (6.4%)
had a BCVA below 1.0 logMAR. For eyes that at nadir were
off-chart, 24.4% had a CRR, compared with 53.9% from
those between 1.0—1.68 logMAR and 45.5% of those better
than 1.0 logMAR at nadir (Supplemental Digital Content,
Data E2, http://links.lww.com/WNO/A408).
The overall outcome resulting from the shift of patients
across BCVA categories is visualized in Figure 3.
Safety
The cumulative exposure to idebenone in the SP was 1,981
patient-months. Although patient adherence data are not
available, idebenone (150 mg tablets) was prescribed at
a daily dose of 900 mg (300 mg three times a day).
In the 111 patients treated with idebenone, 65 AEs
(60.7% mild; 4.5% moderate; 4.5% severe) were reported
in 32 patients. The most common AEs were gastrointestinal
(n = 17), with diarrhea the most frequent (n = 5). Nine
serious AEs were reported in 7 patients (all considered “not
related” to treatment). Three cases with a fatal outcome,
unrelated to idebenone use, were reported. Nine patients
discontinued treatment because of AEs.
DISCUSSION
The data from this EAP provide unique and novel insights
into the efficacy and safety of idebenone treatment in
LHON in a real-world setting. Patients with LHON
experience rapid vision loss, thus 2 therapeutic goals may
be defined depending on the stage of progression. For
patients who have suffered a relevant degree of vision loss,
the aim is to improve the BCVA as much as possible, at
least to a CRR. For patients with relevant residual vision,
stabilization of BCVA is important, particularly if ‘severe
vision loss’ has not yet been reached. Achieving either goal,
CRR or CRS, may be considered a clinically relevant benefit
for patients.
Clinically Relevant Stabilization
Vision loss in untreated patients is rapid (5), with more than
70% of eyes progressing to a BCVA worse than 1.0
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TABLE 1. Patient demographics and baseline (BL) values*. Efficacy population (EP) by mutation†
All G11778A G3460A T14484C
Patients in the EP 87/87 (100%) 54/87 (62.1%) 17/87 (19.5%) 16/87 (18.4%)
Treatment duration
(mo)‡
25.6 ± 16.9 (2.4–70.4) 24.9 ± 17.4 (3.2–70.4) 27.7 ± 16.7 (4.4–61.0) 25.5 ± 16.0 (2.4–53.8)
Gender male 71/87 (82%) 45/54 (83%) 13/17 (77%) 13/16 (81%)
Age at onset (y) 31.4 ± 17.3 (6.6–78.9) 33.3 ± 17.5 (12.1–78.9) 28.4 ± 16.8 (6.6–64.5) 28.1 ± 16.9(8.5–56.2)
Adolescent at onset
(age 12–17 y)
22/87 (25.3%) 11/54 (20.4%) 6/17 (35.3%) 5/16 (31.3%)
Childhood onset
(,12 y of age)
3/87 (3.4%) 0/54 (0%) 1/17 (5.9%) 2/16 (12.5%)
Time since onset at
baselinek (mo)
4.6 ± 3.0 (0.3–11.5) 4.3 ± 2.7 (0.4–11.4) 5.9 ± 3.7 (0.3–11.5) 4.4 ± 2.8 (0.9–9.3)
Interval of onset
between eyes¶#
(mo)
1.7 ± 2.5 (0.0–12.6) 1.8 ± 2.5 (0.0–10.0) 1.9 ± 3.1 (0.0–12.6) 0.9 ± 1.3 (0.0–4.7)
BCVA at baseline
[logMAR]§
1.23 ± 0.52 (20.18–1.8) 1.22 ± 0.59 (20.18–1.8) 1.37 ± 0.38 (0.40–1.80) 1.12 ± 0.39 (0.28–1.80)
Baseline BCVA off-
chart**
17/87 (20%) 13/54 (24%) 3/17 (18%) 1/16 (6%)
Baseline BCVA from
1.0 to 1.68
logMAR
46/87 (53%) 25/54 (46%) 11/17 (65%) 10/16 (63%)
Baseline BCVA ,1.0
logMAR
24/87 (28%) 16/54 (30%) 3/17 (18%) 5/16 (31%)
Values are given as n (%) or mean ± SD and minimum–maximum (in parentheses); percentages may not total to 100% due to rounding.
*Data cut-off: June 2018.
†For information on EP flow see Supplemental Digital Content, Supplemental Data A, http://links.lww.com/WNO/A407.
‡Treatment duration was not predetermined and was decided by the treating physician according to his/her criteria as per routine clinical
practice.
§BCVA off-chart values are imputed to 1.8 logMAR see Supplemental Digital Content, Supplemental Data A, http://links.lww.com/WNO/
A407.
kTime since onset: time from symptoms onset to start of treatment (baseline) in the most recently affected eye.
¶Three patients were reported by the treating physician to have one asymptomatic eye at baseline.
#Time between onset of first and second affected eye.
**Off-chart values: not reading any letter on the ETDRS chart at 1 m (i.e., .1.68 logMAR) (Supplemental Digital Content, Supplemental
Data A, http://links.lww.com/WNO/A407).
BCVA, best-corrected visual acuity; CRR, clinically relevant recovery; CRS, clinically relevant stabilization; logMAR, logarithm of the minimal
angle of resolution; mo, months; y, years.
TABLE 2. Clinically relevant stabilization (CRS) for the subset of patients with a BCVA at baseline ,1.0 logMAR.
Efficacy population (EP)*† by mutation
All G11778A G3460A T14484C
BCVA stabilization:
Patients with CRS‡
12/24 (50%) 7/16 (44%) 1/3 (33%) 4/5 (80%)
BCVA at baseline
[logMAR]
0.47 ± 0.36 (20.18–0.96) 0.31 ± 0.34 (0.18–0.88) 0.94 0.62 ± 0.28 (0.28–0.96)
BCVA at last
observation
[logMAR]
0.29 ± 0.29 (20.16–0.8) 0.35 ± 0.34 (20.16–0.8) 0.34 0.17 ± 0.29 (20.14–0.42)
Treatment duration
[months]§
30.1 ± 19 (9.9–67.8) 25.5 ± 20.6 (10.7–67.8) 40.0 35.8 ± 18.6 (9.9–53.8)
Values are given as n (%) or mean ± SD and minimum–maximum (in parentheses); Percentages may not total to 100% due to rounding.
*Data cut-off: June 2018.
†For information on EP flow see Supplemental Digital Content, Supplemental Data A, http://links.lww.com/WNO/A409.
‡CRS: BCVA had to be maintained in an eye with BCVA ,1.0 logMAR at start of the treatment.
§Calculations only consider patients with CRS (12 patients).
BCVA, best-corrected visual acuity; CRS, clinically relevant stabilization; logMAR, logarithm of the minimal angle of resolution.
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logMAR (20/200 Snellen) within 3 months (4,18). Accord-
ingly, only 27.6% patients had a BCVA better than 1.0
logMAR at baseline (mean 4.6 months after a symptom
onset) (Table 1). Although it is to be expected that most
patients would further progress if untreated, with treat-
ment, half of them (12/24, 50.0%) maintained a BCVA
below this threshold after an average follow-up time of
24.3 months. One key limitation of CRS is that it does
not take into account the fact that the BCVA could still
have deteriorated significantly, but not enough to cross the
1.0 logMAR threshold, so it would still qualify as CRS
despite having deteriorated. Interestingly, the mean BCVA
for these patients improved from 0.47 to 0.29 logMAR,
corresponding to 9 letters on the ETDRS chart. Compared
with the natural disease course, early idebenone treatment
provides an opportunity to prevent severe vision loss over
a timespan when further BCVA deterioration would be
expected for most patients (19).
In most cases, the journey to LHON diagnosis after
a symptom onset takes weeks or months, usually not
allowing for treatment initiation until the second eye
becomes affected. Notably, in the EAP, only 3 patients
TABLE 3. Clinically relevant recovery (CRR) by patient. Efficacy population (EP)*† by mutation
All G11778A G3460A T14484C
BCVA recovery: Patients
with a CRR ‡
40/87 (46.0%) 21/54 (39%) 7/17 (41%) 12/16 (75%)
Time to an initial CRR
[months]
9.5 ± 7.0 (2.5–26.5) 11.2 ± 7.8 (2.5–26.5) 7.3 ± 3.4 (2.5–12.9) 7.8 ± 6.8 (3.0–25.6)
Magnitude of recovery at
initial CRR
logMAR 0.45 ± 0.31 0.20–1.62 0.39 ± 0.32 0.20–1.62 0.39 ± 0.20 0.22–0.76 0.60 ± 0.30 0.22–1.20
No. of letters ETDRS 22 ± 15 (10–81) 19 ± 16 (10–81) 19 ± 10 (11–38) 30 ± 15 (11–60)
Magnitude of recovery at
last observation
logMAR 0.72 ± 0.46 0.20–1.80 0.52 ± 0.39 0.20–1.76 0.61 ± 0.31 0.24–1.10 1.12 ± 0.40 0.46–1.80
No. of letters ETDRS 36 ± 23 (10–90) 26 ± 19 (10–88) 30 ± 15 (12–55) 56 ± 20 (23–90)
Values are given as n (%) or mean ± SD and minimum–maximum (in parentheses); percentages may not total to 100% due to rounding.
*Data cut-off June 2018.
†For information on EP flow see Supplemental Digital Content, Supplemental Data A, http://links.lww.com/WNO/A407.
‡CRR is improvement from an off-chart BCVA to on-chart by the equivalent of at least one full line on an ETDRS chart (5 letters) or an
improvement in an on-chart BCVA by the equivalent of at least 2 lines (10 letters).
BCVA, best-corrected visual acuity; CRR, clinically relevant recovery; ETDRS, Early Treatment Diabetic Retinopathy Study; logMAR, loga-
rithm of the minimal angle of resolution.
FIG. 1. Kaplan–Meier curves of clinically relevant recovery (CRR). Cumulative percentage of total number of patients and
eyes, respectively, with a CRR, as a function of treatment duration, in the efficacy population (EP).
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had one unaffected eye at the start of treatment, 2 of which
maintained this status at the LV. Although the numbers are
low, this contrasts with a previous case series, in which all 6
patients starting idebenone treatment with an unaffected eye
subsequently experienced a BCVA decrease in these eyes (8).
Although this is a good indication of a favorable effect, the
small numbers mean it remains to be seen whether idebe-
none can indeed prevent the onset of symptoms, that is, in
patients starting treatment “in-between” onset in the eyes.
This can be further explored once better referral and earlier
diagnosis result in widespread early treatment of the disease.
Clinically Relevant Recovery
Vision loss in patients with LHON is mostly permanent
(19). However, in the EAP, almost one in 2 patients (40/
87, 46.0%) treated with idebenone experienced a CRR after
a mean treatment duration of 9.48 months. This is compa-
rable with the 45.5% (20/44) responder rate for idebenone-
treated patients in a case series using similar criteria to
define recovery (8), and of 42.9% (6/14) reported for
a smaller patient cohort treated with idebenone and vitamin
B2 (9). Both of these retrospective studies reported lower
rates of recovery, 32.2% (8) and 28.6% (9), for the
untreated, in-study control groups. Although the EAP did
not have a control group, a recently conducted, large retro-
spective case record survey provided rates of CRR using
identical criteria as in the EAP (20,21). In this study,
31.1% of untreated patients (23/74) experienced a CRR,
a proportion again in line with the untreated groups of the 2
cohort studies (8,9).
Rate of Recovery as a Function of Treatment
Duration
This EAP provides a large data set in patients treated for an
average of more than 2 years (in RHODOS was 6 months).
FIG. 2. Magnitude of mean BCVA recovery over the course of time in eyes with a CRR. Magnitude of best-corrected visual
acuity (BCVA) recovery in eyes with a clinically relevant recovery (CRR). Left: Average BCVA observed at baseline (BL), nadir,
initial observation of CRR, and at the last observation visit (LV) for all eyes that experienced a CRR (n = 67). Right:
Improvement of BCVA over the course of time, at given treatment durations, in those eyes that experienced a CRR within 6
months of treatment initiation and where follow-up data were available (n = 22). All mutations. All off-chart VA values were
imputed to 1.8 logMAR. Error bars indicate the 95% CI.
FIG. 3. Shift of patients, over the course of treatment time, across
categories of BCVA (efficacy population, n= 87). Bar chart for dis-
tribution of patients based on categories for the best-corrected
visual acuity (BCVA) at baseline (BL), at nadir, and at the last
observation visit (LV) mutations. EP, efficacy population.
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In the EAP, time from start of therapy to initial
observation of CRR varies from 2.5 to 26.5 months (Table
3). This provides evidence for a benefit of longer idebenone
treatment in LHON because only 45.0% of the total res-
ponders had experienced their first recovery by 6 months.
The responder rate increased with treatment duration up to
12 months, but 33% patients experienced a CRR later, with
some only showing initial improvement after 24 months of
treatment (Fig. 1).
Magnitude of Recovery as a Function of
Treatment Duration
Evaluating the impact of continued therapy after an initial
CRR has been observed is very relevant. At the initial CRR,
the average magnitude of best recovery by subject was 23
letters, which increased to 36 letters (7 lines ETDRS) by the
LV. This effect was also observed for individual eyes with
a CRR (n = 67) where after first worsening to a nadir, later
improved at initial observation of CRR and further at the LV
(mean recovery of 35 letters from nadir) (Fig. 2, left). Finally,
in a subset of eyes demonstrating an early CRR (within 6
months), the magnitude of CRR continued to increase with
prolonged treatment, from 21 letters after 6 months to 50
letters by the LV (average treatment duration of 35 months).
Rate of Recovery and Outcome as a Function
of Vision Loss During Therapy
An interesting question to address is whether the results of
therapy are dependent on the degree of BCVA loss, both in
terms of responder rate and to a change in categorical
BCVA outcomes, as defined by BCVA thresholds related to
quality of life (17). At the start of treatment, 27.6% patients
presented with a BCVA ,1.0 logMAR and 19.5% were
already off-chart, highlighting the rapid vision loss described
elsewhere (11,19,22). Visual outcomes showed some fur-
ther worsening after treatment initiation, reaching a nadir.
At the final available assessment, however, visual outcomes
were markedly improved compared to nadir, with more
than a tripling of patients with a BCVA ,1.0 logMAR
from nadir (9.2%) to the LV (32.2%) and a reduction in
off-chart patients (44.8%–32.2%) (Fig. 3). Although
a CRR can be achieved both in on-chart and off-chart eyes,
the proportion of CRR was higher for eyes being on-chart at
nadir (53.9%) than for eyes being off-chart at nadir
(24.4%) (Table 4 and Supplemental Digital Content,
Data E2, http://links.lww.com/WNO/A408).
Also, for responders, the magnitude of improvement can
be very marked, regardless of the severity at nadir.
Impact of Leber Hereditary Optic Neuropathy
Mutation on the Reported Analyses
The most frequent mitochondrial gene variant causing
LHON, G11778A, is considered to correlate with the most
severe prognosis, whereas the T14484C mutation is
typically associated with a milder phenotype, and the
G3460A mutation has an intermediate prognosis
(2,10,22). The largest subgroup of patients in the EAP were
G11778A. They experienced a slightly lower rate of CRS
than the entire cohort, a lower rate of CRR, a smaller mag-
nitude of recovery by the LV, and longer treatment dura-
tion to recovery. As expected, although with a small number
of patients, T14484C patients had the highest rate of CRS
and CRR, the largest magnitude of recovery, and the short-
est treatment duration before a CRR, whereas the corre-
sponding rates for patients with the G3460A mutation
mostly fell in between the other 2 mutations (Tables 1–3).
With the obvious limitations resulting from varying
observation duration and definitions of treatment response
(10,15,23–27), rates of spontaneous recovery of VA have
been documented in several studies and can be as low as 4%
for the G11778A mutation (23–27). In the RHODOS
placebo group, spontaneous recovery across all mutations
TABLE 4. Clinically relevant recovery (CRR) by individual eyes as a function of BCVA at nadir. Efficacy population
(EP)*†
VA Category at
Nadir Eyes
Eyes With a CRR‡
Within Category
Eyes With a CRR and BCVA [logMAR] at the Last Observation
BCVA . 1.0 .0.5 BCVA ,1.0 BCVA # 0.5
Off-chart 86/173 (49.7%) 21/86 (24%) 14 2 5
From 1.0 to 1.68
logMAR
76/173 (44%) 41/76 (54%) 12 13 16
Below 1.0 logMAR 11/173 (6%) 5/11 (46%) na 0 5
All§ 173/173 (100%) 67/173 (39%) 26 15 26
Values are given as n (%); Percentages may not total to 100% due to rounding.
*Data cut-off June 2018.
†For information on EP flow see Supplemental Digital Content, Supplemental Data A, http://links.lww.com/WNO/A407.
‡CRR is improvement from an off-chart BCVA to on-chart by the equivalent of at least one full line on an ETDRS chart (5 letters) or an
improvement in an on-chart BCVA by the equivalent of at least 2 lines (10 letters) at LV.
§One patient had vision loss in one eye not related to LHON.
BCVA, best-corrected visual acuity; CRR, clinically relevant recovery; logMAR, logarithm of the minimal angle of resolution; na, not
applicable.
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occurred in 10.3% of patients over 6 months (15). Overall,
the CRR rate observed in our data exceeds the reported rates
of spontaneous recovery.
Idebenone was well tolerated, with a good safety profile,
in line with results from the RHODOS trial (15). No new
safety signals have been observed.
Although our analysis has the inherent limitations from
the retrospective nature of the data and a lack of control
group, it provides, however, an important view of long-term
response and tolerability of idebenone in patients within the
first year of disease onset in the second eye in a real-world
setting.
CONCLUSIONS
Our results suggest that the overall outcome of idebenone
treatment indicates a better long-term prognosis than
expected from limited natural history data. Although
treatment response is observed despite severity of visual
impairment, early treatment initiation improves the chances
of response.
A treatment duration of at least 18–24 months is needed
to maximize the probability of CRR because a certain
degree of transient deterioration to a nadir may occur
despite therapy initiation and continued treatment after
an initial CRR provides further benefit. The risk balance
of idebenone 900 mg/day is in line with the previously
published randomized placebo-controlled clinical trial.
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